Human abuse liability data is now considered a critical piece of information during the new drug application (NDA) review process for most treatments involving central nervous system (CNS) indications and those with abuse deterrent or tamper resistant properties.
As a global strategic partner for pharmaceutical and biotech companies in Phase I development, PRA’s Early Development Services (EDS) team is highly experienced in all types of early phase studies.
Download the factsheet to learn about:
- Clinical Research Services
- Human Abuse Liability Specialists
- Specialized Patient Populations
- Facility Features/Services
- Human Abuse Liability Facilities
PRA International is sponsoring this year’s Exploratory Clinical Development World Europe event, happening this 3-5 June in London. For more information, click here